A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab

Yuta Kasagi, Eiji Oki, Koji Ando, Yasue Kimura, Toru Ikegami, Hiroshi Saeki, Masaru Morita, Tetsuya Kusumoto, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.

Original languageEnglish
Pages (from-to)382-386
Number of pages5
JournalCase Reports in Oncology
Issue number2
Publication statusPublished - May 2013

All Science Journal Classification (ASJC) codes

  • Oncology


Dive into the research topics of 'A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab'. Together they form a unique fingerprint.

Cite this